Explore

Streams

About Index

Index

By TNW

South San Francisco

10–100 Companies

Related cities

10–100 companies in South San Francisco
Show all

Genentech

insitro

Biotechnology +2

MyoKardia

Sutro Biopharma

Freenome

Personal Health +2

SuccessFactors

Enterprise Software +3

Plenty

Theravance

Dispatch

Counsyl

Machine Learning +3

Kinestral Technologies, Inc.

CytoVale

Veracyte, Inc.

Principia Biopharma

Titan Pharma

All companies in South San Francisco

Terms of Service Privacy Policy Cookie Statement

Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

News

Funding rounds

Acquisitions

Companies

Investors

Filter companies

Companies

59

Growing

Deals 2021 Q4

No investments

No acquisitions

Index Pro Account

Upgrade your account to download a CSV export of companies on any list

Upgrade account

Freenome gets $290M from Roche as it preps blood-based cancer test’s next steps

Sutro Biopharma Stock (STRO): Why The Price Substantially Fell

Sutro Biopharma Stock (STRO): Why The Price Substantially Fell Today

Sutro Biopharma Stock (STRO): Why The Price Increased Today

Calithera Biosciences (CALA) Stock: Why The Price Jumped Today

Theravance’s lead drug fails in Phase 3, triggers a restructuring cutting 75% of staff

$12,000,000 Venture capital (Series A)

Mindera Raises Over $12 Million Series A-2 Financing

insitro raises $400M for machine learning-powered drug discovery efforts

$400,000,000 Venture capital (Series C)

insitro raises $400M for machine learning-powered drug discovery efforts

insitro Raises $400 Million in Series C Financing

insitro Raises $400 Million in Series C Financing

BMS joins forces with insitro to develop neurodegenerative treatments

insitro Bolsters Machine–Learning Platform with Haystack Sciences Acquisition

Koller’s insitro snaps up Haystack to build up machine learning tech

$140,000,000 Venture capital (Series D)

Plenty has raised over $500 million to grow fruits and veggies indoors

Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B

Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More

$270,000,000 Venture capital (Series C)

,

Freenome Closes $270M Series C Financing

Genentech Gets FDA OK for Injectable Rare Neuroimmune Disease Drug

Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia